Results 131 to 140 of about 165,865 (302)

[Oncogenes as indicators of occupational exposure to carcinogenic agents]

, 1993
Oncogenes are a class of genes capable of inducing neoplastic alterations of the cell. Recently, oncogenes have received greater attention in environmental medicine, since they may be useful tools for monitoring individuals exposed to carcinogenic ...
Costa, L. G, Manzo, L., Castoldi, A. F
core  

Oncogenes Induce Replication Stress via Intragenic Replication Origins

, 2018
Oncogenes induce premature S phase, resulting in replication–transcription conflicts and replication stress.

core   +1 more source

Molecular Glue cc‐885 Inhibits VHL‐Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation

Advanced Science, EarlyView.
VHL‐deficient kidney cancer lacks effective treatments. This study reveals that the molecular glue degrader cc‐885 hijacks the cellular recycling system to selectively destroy the oncogenic protein ETS1, effectively killing VHL‐mutant tumors. Combining CC‐885 with the approved drug belzutifan achieves powerful synergy, offering a promising new ...
Taowei Yang, Qihao Li, Kun Ye, Kezhi Liu, Mi Zhou, Minyu Chen, Lican Liao, Kangbo Huang, Zhu Wang, Qiong Deng, Jieyan Wang, Meiyu Jin, Xu Chen, Hui Liang, Jiaxing Zhang, Junhang Luo   +15 more
wiley   +1 more source

Oncogenes and tumor suppressors with cancer-specific AS events.

, 2013
Oncogenes and tumor suppressors with cancer-specific AS events.
Chunjiang He (374122), Rongjia Zhou (164123), Fang Zhou (43765), Hanhua Cheng (164121), Zhixiang Zuo (374123)   +4 more
core   +1 more source

TSPYL5 Promotes Triple‐Negative Breast Cancer Metastasis by Antagonizing USP10‐Mediated PTEN Stabilization to Unleash a ZEB1‐Dependent EMT Program

Advanced Science, EarlyView.
The hyperactivation of PI3K/AKT signaling in PTEN wild‐type triple‐negative breast cancer represents a clinical paradox. We delineate a novel post‐translational regulatory axis wherein the oncogene TSPYL5 competitively antagonizes the deubiquitinase USP10.
Jiaying Shi, Ming Yi, Shengyu Xie, Zhaokun Wang, Xinyue Zhang, Yangwei Zhang, Rui Tang, Yuan Yang, Yunqiang Liu   +8 more
wiley   +1 more source

Growth regulation by oncogenes — new insights from model organisms

, 2001
A great deal of work has focused on how oncogenes regulate the cell cycle during normal development and in cancer, yet their roles in regulating cell growth have been largely unexplored.
Prober, David A., Edgar, Bruce A.
core  

Effects of expressed oncogenes on the induction of liver tumors.

, 2013
Effects of expressed oncogenes on the induction of liver tumors.
Hye-Lim Ju (395738), Simon Weonsang Ro (395741), Sook In Chung (395740), Sinhwa Baek (395739), Jinsil Seong (41007), Sang Hoon Ahn (131984), Kwang-Hyub Han (131978), Do Young Kim (131974)   +7 more
core   +1 more source

Genome‐Wide In Vivo RNAi Screening Identifies HOXD4 as a Tumor Metastasis Suppressor in Colorectal Cancer

Advanced Science, EarlyView.
Metastasis remains a major challenge in colorectal cancer. Using an in vivo shRNA screening system, this study identifies Homeobox D4 as a key metastasis suppressor. Reduced Homeobox D4 expression is associated with aggressive tumor features. Functional and mechanistic analyses show that it inhibits epithelial‐mesenchymal transition by repressing ...
Zhi‐hua Ye, Wen‐jing Luo, Lu Li, Wen‐di Shuai, Ling Zhou, You‐fa Duan, Xue Chen, Jun‐kai Zhang, Wenlin Huang, Ran‐yi Liu   +9 more
wiley   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source